About this trial
The study is about the importance of each follow-up visit after activating a new cochlear implant in addition to evaluating the effectiveness and efficiency of a new programming strategy from Cochlear Americas. Investigators are looking for patients who have recently selected Cochlear Americas as their cochlear implant manufacturer of choice for their upcoming surgery. The aim of this study is to determine if 1) patient outcomes remain stable when reducing follow-up appointments and 2) Cochlear's population mean mapping can produce similar outcomes with patients while additionally reducing appointment times. The hypothesis is that using population mean mapping and reducing the number of follow-up visits after activation will yield similar performance outcomes to a standard of care while decreasing the length of appointment times and number of appointments needed for each patient.
Eligibility criteria
Qualifiers
Postlingually deafened
Adults (18+)
New cochlear implant recipients with Cochlear Americas devices; identified prior to activation
Able to perform follow-up testing tasks (repeating words/sentences, indicating they heard a sound stimulus, completing questionnaires)
Disqualifiers
Patients who select other cochlear implant manufactured devices
Pre-lingually deafened
Multiple disabilities
Unable to perform follow-up testing tasks (repeating words/sentences, indicating they heard a sound stimulus, completing questionnaires)
Trial design
Treatments tested in this trial
- Changes in traditional follow-up
- Population mean mapping
Treatment groups
Sponsors and collaborators
Massachusetts Eye and Ear Infirmary
Lead sponsor
Cochlear
Collaborator